The New York State Stem Cell Science (NYSTEM) program was established by New York State (NYS) in 2007 to position New York as a global leader in research, develop new therapies to alleviate disease, improve health, and grow our life sciences sector. Across NYS, NYSTEM research is leading to the development of clinical therapies for disease such as Alzheimer’s, Parkinson’s, ALS, cancers, spinal cord injuries, diabetes, sickle cell disease and other conditions. Such research is also now informing the search for new and better COVID-19 treatments. Many of the diseases for which NYSTEM-funded researchers have developed promising new clinical therapies are those disproportionately impacting communities of color. NYSTEM has also funded programs at institutions across New York State that provide training for early career scientists.
Beyond significant breakthroughs in laboratory research and workforce development, NYSTEM research has also led to the creation of new life sciences companies in NYS and is attracting significant additional federal and private sector investment. To-date, NYSTEM has supported more than 400 research projects at 39 institutions across NYS, as well as more than 2,000 scientists and laboratory staff.
At Weill Cornell Medicine, current NYSTEM projects are looking into areas including:
- Cardiovascular disease
- Age-related macular degeneration
- Sickle cell disease
For more information on NYSTEM, please visit: